{
    "evidence": [
        {
            "id": 2,
            "name": "EID2",
            "description": "GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.",
            "disease": {
                "id": 2,
                "name": "Gastrointestinal Stromal Tumor",
                "display_name": "Gastrointestinal Stromal Tumor",
                "doid": "9253",
                "url": "http://www.disease-ontology.org/?id=DOID:9253"
            },
            "drugs": [],
            "rating": 3,
            "evidence_level": "B",
            "evidence_type": "Diagnostic",
            "clinical_significance": "Negative",
            "evidence_direction": "Supports",
            "variant_origin": "Somatic",
            "drug_interaction_type": null,
            "status": "accepted",
            "type": "evidence",
            "source": {
                "id": 52,
                "name": "A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.",
                "citation": "Lasota et al., 2004, Lab. Invest.",
                "citation_id": "15146165",
                "source_type": "PubMed",
                "asco_abstract_id": null,
                "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15146165",
                "open_access": null,
                "pmc_id": null,
                "publication_date": {
                    "year": 2004,
                    "month": 7
                },
                "journal": "Lab. Invest.",
                "full_journal_title": "Laboratory investigation; a journal of technical methods and pathology",
                "status": "fully curated",
                "is_review": false,
                "clinical_trials": []
            },
            "variant_id": 99,
            "phenotypes": [],
            "assertions": [],
            "gene_id": 38
        },
        {
            "id": 74,
            "name": "EID74",
            "description": "In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.",
            "disease": {
                "id": 15,
                "name": "Thyroid Gland Medullary Carcinoma",
                "display_name": "Thyroid Gland Medullary Carcinoma",
                "doid": "3973",
                "url": "http://www.disease-ontology.org/?id=DOID:3973"
            },
            "drugs": [],
            "rating": 5,
            "evidence_level": "B",
            "evidence_type": "Diagnostic",
            "clinical_significance": "Positive",
            "evidence_direction": "Supports",
            "variant_origin": "Somatic",
            "drug_interaction_type": null,
            "status": "accepted",
            "type": "evidence",
            "source": {
                "id": 44,
                "name": "Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.",
                "citation": "Elisei et al., 2008, J. Clin. Endocrinol. Metab.",
                "citation_id": "18073307",
                "source_type": "PubMed",
                "asco_abstract_id": null,
                "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18073307",
                "open_access": null,
                "pmc_id": null,
                "publication_date": {
                    "year": 2008,
                    "month": 3
                },
                "journal": "J. Clin. Endocrinol. Metab.",
                "full_journal_title": "The Journal of clinical endocrinology and metabolism",
                "status": "fully curated",
                "is_review": false,
                "clinical_trials": []
            },
            "variant_id": 113,
            "phenotypes": [],
            "assertions": [],
            "gene_id": 42
        }
    ],
    "assertions": [
        {
            "id": 9,
            "type": "assertion",
            "name": "AID9",
            "summary": "Supports diagnosis of diffuse intrinsic pontine glioma.",
            "description": "ACVR1 G328V mutations occur within the kinase domain, leading to activation of downstream signaling. Exclusively seen in high-grade pediatric gliomas, supporting diagnosis of diffuse intrinsic pontine glioma.",
            "gene": {
                "name": "ACVR1",
                "id": 154
            },
            "variant": {
                "name": "G328V",
                "id": 1686
            },
            "disease": {
                "id": 2950,
                "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                "doid": "0080684",
                "url": "http://www.disease-ontology.org/?id=DOID:0080684"
            },
            "drugs": [],
            "evidence_type": "Diagnostic",
            "evidence_direction": "Supports",
            "clinical_significance": "Positive",
            "fda_regulatory_approval": false,
            "status": "accepted",
            "nccn_guideline": null,
            "nccn_guideline_version": "",
            "amp_level": "Tier II - Level C",
            "evidence_items": [
                {
                    "id": 4846,
                    "name": "EID4846",
                    "description": "Sequencing of 39 pediatric midline high-grade astrocytomas identified 5 patients with ACVR1 mutations. The authors identified an increase in endogenous phospho-SMAD1/5/8 signal in diffuse intrinsic pontine glioma (DIPG) cells harboring ACVR1 G328V, with corresponding increase in phospho-SMAD1/5/8 staining as well. By PCR, the authors show strong increase in fold change of mRNA expression in downstream proteins of the ACVR1/BMP pathway, ID, ID2, ID3 and SNAI1 in ACVR1-mutant DIPG cell line compared to glioblastoma cells (KNS42 cells). These activating ACVR1 mutations were exclusively in midline high grade astrocytomas (P = 0.0040, Fisher's exact test).",
                    "disease": {
                        "id": 2950,
                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "doid": "0080684",
                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
                    },
                    "drugs": [],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "Diagnostic",
                    "clinical_significance": "Positive",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2149,
                        "name": "Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.",
                        "citation": "Fontebasso et al., 2014, Nat. Genet.",
                        "citation_id": "24705250",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705250",
                        "open_access": true,
                        "pmc_id": "PMC4282994",
                        "publication_date": {
                            "year": 2014,
                            "month": 5
                        },
                        "journal": "Nat. Genet.",
                        "full_journal_title": "Nature genetics",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 1686,
                    "phenotypes": [],
                    "assertions": [
                        {
                            "id": 9,
                            "type": "assertion",
                            "name": "AID9",
                            "summary": "Supports diagnosis of diffuse intrinsic pontine glioma.",
                            "description": "ACVR1 G328V mutations occur within the kinase domain, leading to activation of downstream signaling. Exclusively seen in high-grade pediatric gliomas, supporting diagnosis of diffuse intrinsic pontine glioma.",
                            "gene": {
                                "name": "ACVR1",
                                "id": 154
                            },
                            "variant": {
                                "name": "G328V",
                                "id": 1686
                            },
                            "disease": {
                                "id": 2950,
                                "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                                "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                                "doid": "0080684",
                                "url": "http://www.disease-ontology.org/?id=DOID:0080684"
                            },
                            "drugs": [],
                            "evidence_type": "Diagnostic",
                            "evidence_direction": "Supports",
                            "clinical_significance": "Positive",
                            "fda_regulatory_approval": false,
                            "status": "accepted"
                        }
                    ],
                    "gene_id": 154
                },
                {
                    "id": 6955,
                    "name": "EID6955",
                    "description": "In a study sequencing 61 patients (median age 6.3) with diffuse intrinsic pontine glioma (DIPG), 12 variants affecting ACVR1 were observed. Five patients had G328V within the kinase domain. The ACVR1 G328V mutation was expressed using the pCDH511b vector in immortalized normal human astrocytes (iNHAs) where it activated downstream BMP signaling and enhanced cell growth. Activating ACVR1 mutations are recurrent and support diagnosis of high grade glioma. PEDIATRIC",
                    "disease": {
                        "id": 2950,
                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "doid": "0080684",
                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
                    },
                    "drugs": [],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "Diagnostic",
                    "clinical_significance": "Positive",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2680,
                        "name": "Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.",
                        "citation": "Buczkowicz et al., 2014, Nat. Genet.",
                        "citation_id": "24705254",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705254",
                        "open_access": true,
                        "pmc_id": "PMC3997489",
                        "publication_date": {
                            "year": 2014,
                            "month": 5
                        },
                        "journal": "Nat. Genet.",
                        "full_journal_title": "Nature genetics",
                        "status": "partially curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 1686,
                    "phenotypes": [],
                    "assertions": [
                        {
                            "id": 9,
                            "type": "assertion",
                            "name": "AID9",
                            "summary": "Supports diagnosis of diffuse intrinsic pontine glioma.",
                            "description": "ACVR1 G328V mutations occur within the kinase domain, leading to activation of downstream signaling. Exclusively seen in high-grade pediatric gliomas, supporting diagnosis of diffuse intrinsic pontine glioma.",
                            "gene": {
                                "name": "ACVR1",
                                "id": 154
                            },
                            "variant": {
                                "name": "G328V",
                                "id": 1686
                            },
                            "disease": {
                                "id": 2950,
                                "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                                "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                                "doid": "0080684",
                                "url": "http://www.disease-ontology.org/?id=DOID:0080684"
                            },
                            "drugs": [],
                            "evidence_type": "Diagnostic",
                            "evidence_direction": "Supports",
                            "clinical_significance": "Positive",
                            "fda_regulatory_approval": false,
                            "status": "accepted"
                        }
                    ],
                    "gene_id": 154
                }
            ],
            "acmg_codes": [],
            "drug_interaction_type": null,
            "fda_companion_test": false,
            "allele_registry_id": "CA16602802",
            "phenotypes": [],
            "variant_origin": "Somatic"
        }
    ],
    "genes": [
        {
            "id": 38,
            "name": "PDGFRA",
            "entrez_id": 5156,
            "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.",
            "variants": [
                {
                    "name": "Exon 18 Mutation",
                    "id": 2623,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "Fusion",
                    "id": 567,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Amplification",
                    "id": 716,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "D842_M844del",
                    "id": 1518,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "Overexpression",
                    "id": 2944,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "Mutation",
                    "id": 3274,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "FIP1L1-PDGFRA T674I",
                    "id": 577,
                    "evidence_items": {
                        "accepted_count": 3,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "TNKS2-PDGFRA",
                    "id": 774,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "P577S",
                    "id": 862,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "D842I",
                    "id": 98,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "V561A",
                    "id": 247,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "D842Y",
                    "id": 100,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "R841K",
                    "id": 863,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "H845Y",
                    "id": 864,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "G853D",
                    "id": 865,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "V561D",
                    "id": 941,
                    "evidence_items": {
                        "accepted_count": 4,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "L579M",
                    "id": 1540,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "W559_R560DELWR",
                    "id": 1539,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "I843DEL",
                    "id": 101,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "D842_H845DELDIMH",
                    "id": 943,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "D842V",
                    "id": 99,
                    "evidence_items": {
                        "accepted_count": 11,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "FIP1L1-PDGFRA",
                    "id": 574,
                    "evidence_items": {
                        "accepted_count": 5,
                        "rejected_count": 1,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "BCR-PDGFRA",
                    "id": 2971,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "D842_I843delinsVM",
                    "id": 102,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "V658A",
                    "id": 3205,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                }
            ],
            "aliases": [
                "PDGFRA",
                "PDGFR2",
                "PDGFR-2",
                "CD140A"
            ],
            "type": "gene"
        },
        {
            "id": 42,
            "name": "RET",
            "entrez_id": 5979,
            "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistence. No RET-specific agents are currently clinically available but several promiscuous kinase inhibitors that target RET, among others, have been approved for MTC treatment.",
            "variants": [
                {
                    "name": "Fusion",
                    "id": 1687,
                    "evidence_items": {
                        "accepted_count": 6,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "Mutation",
                    "id": 1690,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 4
                    }
                },
                {
                    "name": "Overexpression",
                    "id": 597,
                    "evidence_items": {
                        "accepted_count": 3,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "KIF5B-RET V804L",
                    "id": 1688,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "KIF5B-RET G810A",
                    "id": 1689,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "C634R",
                    "id": 1700,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "KIF5B-RET",
                    "id": 273,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "CCDC6-RET",
                    "id": 626,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "V804M",
                    "id": 2568,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "M918T",
                    "id": 113,
                    "evidence_items": {
                        "accepted_count": 6,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "C609Y",
                    "id": 1260,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "C634W",
                    "id": 112,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "G810",
                    "id": 3033,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "G810C",
                    "id": 3226,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "G810S",
                    "id": 3227,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "Y806C",
                    "id": 3228,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "Y806N",
                    "id": 3229,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "V738A",
                    "id": 3230,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                }
            ],
            "aliases": [
                "RET",
                "RET-ELE1",
                "PTC",
                "MTC1",
                "MEN2B",
                "MEN2A",
                "HSCR1",
                "CDHR16",
                "CDHF12"
            ],
            "type": "gene"
        },
        {
            "id": 154,
            "name": "ACVR1",
            "entrez_id": 90,
            "description": "",
            "variants": [
                {
                    "name": "Gain-of-Function",
                    "id": 2061,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "MUTATION",
                    "id": 2983,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "G328E",
                    "id": 2283,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "G328V",
                    "id": 1686,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "G328W",
                    "id": 2280,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "R258G",
                    "id": 2275,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                }
            ],
            "aliases": [
                "ACVR1",
                "TSRI",
                "SKR1",
                "FOP",
                "ALK2",
                "ACVRLK2",
                "ACVR1A",
                "ACTRI"
            ],
            "type": "gene"
        }
    ],
    "variants": [
        {
            "id": 99,
            "entrez_name": "PDGFRA",
            "entrez_id": 5156,
            "name": "D842V",
            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
            "gene_id": 38,
            "type": "variant",
            "variant_types": [
                {
                    "id": 47,
                    "name": "missense_variant",
                    "display_name": "Missense Variant",
                    "so_id": "SO:0001583",
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                }
            ],
            "civic_actionability_score": 100.5,
            "coordinates": {
                "chromosome": "4",
                "start": 55152093,
                "stop": 55152093,
                "reference_bases": "A",
                "variant_bases": "T",
                "representative_transcript": "ENST00000257290.5",
                "chromosome2": null,
                "start2": null,
                "stop2": null,
                "representative_transcript2": null,
                "ensembl_version": 75,
                "reference_build": "GRCh37"
            },
            "evidence_items": [
                {
                    "id": 4059,
                    "name": "EID4059",
                    "description": "In an in vitro study, Ba/F3 cells expressing PDGFRA D842V mutation (overexpression) demonstrated resistance to sunitinib treatment. Sensitivity was determined by assessing PDGFRA auto-phosphorylation and cell proliferation.",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 157,
                            "name": "Sunitinib",
                            "ncit_id": "C71622",
                            "aliases": [
                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
                            ]
                        }
                    ],
                    "rating": null,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 192,
                        "name": "Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.",
                        "citation": "Prenen et al., 2006, Clin. Cancer Res.",
                        "citation_id": "16638875",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16638875",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2006,
                            "month": 4,
                            "day": 15
                        },
                        "journal": "Clin. Cancer Res.",
                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 4057,
                    "name": "EID4057",
                    "description": "In an in vitro study, gastrointestinal tumor (GIST) cells (endogenous expression) and Ba/F3 murine cells (overexpression) with the PDGFRA D842V mutation were associated with sensitivity to dasatinib treatment (GIST IC50: 47nM, Ba/F3 IC50: 62 nM). Sensitivity was determined by assessing cell proliferation, apoptosis and PDGFRA auto-phosphorylation.",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 20,
                            "name": "Dasatinib",
                            "ncit_id": "C38713",
                            "aliases": [
                                "Sprycel",
                                "Dasatinib Monohydrate",
                                "Dasatinib Hydrate",
                                "BMS-354825",
                                "5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate"
                            ]
                        }
                    ],
                    "rating": null,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 2041,
                        "name": "Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.",
                        "citation": "Dewaele et al., 2008, Clin. Cancer Res.",
                        "citation_id": "18794084",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18794084",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2008,
                            "month": 9,
                            "day": 15
                        },
                        "journal": "Clin. Cancer Res.",
                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 738,
                    "name": "EID738",
                    "description": "823 patients with GIST under therapy with imatinib were genotyped for this study. 18 patients (2%) with PDGFRA mutations were identified. In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months).",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 5,
                            "name": "Imatinib",
                            "ncit_id": "C62035",
                            "aliases": [
                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 486,
                        "name": "Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.",
                        "citation": "Yoo et al., 2016, Cancer Res Treat",
                        "citation_id": "26130666",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26130666",
                        "open_access": true,
                        "pmc_id": "PMC4843750",
                        "publication_date": {
                            "year": 2016,
                            "month": 4
                        },
                        "journal": "Cancer Res Treat",
                        "full_journal_title": "Cancer research and treatment : official journal of Korean Cancer Association",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 2,
                    "name": "EID2",
                    "description": "GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "Diagnostic",
                    "clinical_significance": "Negative",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 52,
                        "name": "A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.",
                        "citation": "Lasota et al., 2004, Lab. Invest.",
                        "citation_id": "15146165",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15146165",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2004,
                            "month": 7
                        },
                        "journal": "Lab. Invest.",
                        "full_journal_title": "Laboratory investigation; a journal of technical methods and pathology",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 651,
                    "name": "EID651",
                    "description": "When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor.",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 5,
                            "name": "Imatinib",
                            "ncit_id": "C62035",
                            "aliases": [
                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 411,
                        "name": "Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.",
                        "citation": "Hirota et al., 2003, Gastroenterology",
                        "citation_id": "12949711",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/12949711",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2003,
                            "month": 9
                        },
                        "journal": "Gastroenterology",
                        "full_journal_title": "Gastroenterology",
                        "status": "partially curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 15,
                    "name": "EID15",
                    "description": "GIST cancer with D842V mutation is resistant to imatinib.",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 5,
                            "name": "Imatinib",
                            "ncit_id": "C62035",
                            "aliases": [
                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 61,
                        "name": "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",
                        "citation": "Corless et al., 2005, J. Clin. Oncol.",
                        "citation_id": "15928335",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15928335",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2005,
                            "month": 8,
                            "day": 10
                        },
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 5346,
                    "name": "EID5346",
                    "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to imatinib treatment (IC50=2,500 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
                    "disease": {
                        "id": 216,
                        "name": "Cancer",
                        "display_name": "Cancer",
                        "doid": "162",
                        "url": "http://www.disease-ontology.org/?id=DOID:162"
                    },
                    "drugs": [
                        {
                            "id": 537,
                            "name": "Imatinib Mesylate",
                            "ncit_id": "C1687",
                            "aliases": [
                                "STI571",
                                "STI-571",
                                "STI 571",
                                "Glivec",
                                "Gleevec",
                                "CGP57148B",
                                "CGP 57148",
                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 965,
                        "name": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
                        "citation": "Heinrich et al., 2008, J. Clin. Oncol.",
                        "citation_id": "18955458",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18955458",
                        "open_access": true,
                        "pmc_id": "PMC2651076",
                        "publication_date": {
                            "year": 2008,
                            "month": 11,
                            "day": 20
                        },
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "status": "partially curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 4058,
                    "name": "EID4058",
                    "description": "In a prospective study of  137 gastrointestinal stromal tumor patients who failed imatinib treatment, patients with PDGFRA mutation (12/89; 11/12 tumors genotyped as D842V) treated with sunitinib were associated with shorter progression free survival (9wk vs. 50.5wk, HR= 1.8753, P=0.049) and shorter overall survival (40wk vs. 121wk, no statistics) as compared to patients with wild-type PDGFRA (n=10).",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 157,
                            "name": "Sunitinib",
                            "ncit_id": "C71622",
                            "aliases": [
                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
                            ]
                        }
                    ],
                    "rating": null,
                    "evidence_level": "B",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 846,
                        "name": "The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.",
                        "citation": "Rutkowski et al., 2012, BMC Cancer",
                        "citation_id": "22439647",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22439647",
                        "open_access": true,
                        "pmc_id": "PMC3361487",
                        "publication_date": {
                            "year": 2012
                        },
                        "journal": "BMC Cancer",
                        "full_journal_title": "BMC cancer",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 4597,
                    "name": "EID4597",
                    "description": "Patients 29 and 66 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) PDGFRA D842V mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patients took 50 mg sunitib per day. Patient 29 was on a treatment schedule of two weeks on/two weeks off, and patient 66 was scheduled for four weeks on/two weeks off.  Patient 29 experienced stable disease for less than 6 months and patient 66 experienced disease progression. Time to progression was censored at 0.1 weeks for patient 29 and was 10 weeks for patient 66. Overall survival was 99 and censored at 129 weeks for patients 29 and 66.",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 157,
                            "name": "Sunitinib",
                            "ncit_id": "C71622",
                            "aliases": [
                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "C",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 965,
                        "name": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
                        "citation": "Heinrich et al., 2008, J. Clin. Oncol.",
                        "citation_id": "18955458",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18955458",
                        "open_access": true,
                        "pmc_id": "PMC2651076",
                        "publication_date": {
                            "year": 2008,
                            "month": 11,
                            "day": 20
                        },
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "status": "partially curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 7479,
                    "name": "EID7479",
                    "description": "In a phase 2 trial, patients with gastrointestinal stromal tumor (GIST) harboring with PDGFRA D842V or other exon 18 mutation were treated with Avapritinib which have broad activity against oncogenic KIT/PDGFRA mutations including secondary resistance mutations.\nThis trial included 62 patients with PDGRFA exon 18 mutations 56 D842V, 6 non-D842V).\nThe response rate in evaluable patients with PDGFRA exon 18 mutations were 86% (37/43).",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 671,
                            "name": "Avapritinib",
                            "ncit_id": "C123827",
                            "aliases": [
                                "CS3007",
                                "AYVAKIT",
                                "(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine",
                                "PDGFR Alpha/KIT Mutant-specific Inhibitor BLU-285",
                                "BLU-285"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 2968,
                        "name": "Clinical activity of avapritinib in &#x2265; fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).",
                        "citation": "Michael C. Heinrich, 2019, ASCO Annual Meeting, Abstract 11022",
                        "citation_id": "174900",
                        "source_type": "ASCO",
                        "asco_abstract_id": 11022,
                        "source_url": "https://meetinglibrary.asco.org/record/174900/abstract",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2019,
                            "month": 10
                        },
                        "journal": "J Clin Oncol 37, 2019 (suppl; abstr 11022)",
                        "full_journal_title": "Endocrinologia japonica",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": [
                            {
                                "nct_id": "NCT02508532",
                                "name": "(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors",
                                "description": "This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).",
                                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT02508532"
                            }
                        ]
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 4060,
                    "name": "EID4060",
                    "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
                    "disease": {
                        "id": 216,
                        "name": "Cancer",
                        "display_name": "Cancer",
                        "doid": "162",
                        "url": "http://www.disease-ontology.org/?id=DOID:162"
                    },
                    "drugs": [
                        {
                            "id": 157,
                            "name": "Sunitinib",
                            "ncit_id": "C71622",
                            "aliases": [
                                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 965,
                        "name": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
                        "citation": "Heinrich et al., 2008, J. Clin. Oncol.",
                        "citation_id": "18955458",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18955458",
                        "open_access": true,
                        "pmc_id": "PMC2651076",
                        "publication_date": {
                            "year": 2008,
                            "month": 11,
                            "day": 20
                        },
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "status": "partially curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 16,
                    "name": "EID16",
                    "description": "While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 5,
                            "name": "Imatinib",
                            "ncit_id": "C62035",
                            "aliases": [
                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 62,
                        "name": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.",
                        "citation": "Heinrich et al., 2006, J. Clin. Oncol.",
                        "citation_id": "16954519",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16954519",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2006,
                            "month": 10,
                            "day": 10
                        },
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "status": "partially curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 44,
                    "name": "EID44",
                    "description": "In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 21,
                            "name": "Crenolanib",
                            "ncit_id": "C64639",
                            "aliases": [
                                "PDGFR Inhibitor CP-868596",
                                "CP-868596",
                                "CP-868,596",
                                "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine",
                                "4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 80,
                        "name": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.",
                        "citation": "Heinrich et al., 2012, Clin. Cancer Res.",
                        "citation_id": "22745105",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22745105",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2012,
                            "month": 8,
                            "day": 15
                        },
                        "journal": "Clin. Cancer Res.",
                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 2478,
                    "name": "EID2478",
                    "description": "This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Three patients' GISTs harbored PDGFRA D842V. Two of these patients experienced progressive disease and one was unassessable. The authors conclude that this finding is consistent with the work of others suggesting that PDGFRA D842V is an imatinib resistant variant in GIST.",
                    "disease": {
                        "id": 2,
                        "name": "Gastrointestinal Stromal Tumor",
                        "display_name": "Gastrointestinal Stromal Tumor",
                        "doid": "9253",
                        "url": "http://www.disease-ontology.org/?id=DOID:9253"
                    },
                    "drugs": [
                        {
                            "id": 5,
                            "name": "Imatinib",
                            "ncit_id": "C62035",
                            "aliases": [
                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "C",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 412,
                        "name": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.",
                        "citation": "Heinrich et al., 2003, J. Clin. Oncol.",
                        "citation_id": "14645423",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/14645423",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2003,
                            "month": 12,
                            "day": 1
                        },
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "status": "partially curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 2463,
                    "name": "EID2463",
                    "description": "In an in vitro study of imatinib sensitivity, PDGFRA D842V was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842V required 10-20 fold higher concentrations of imatinib as ligand activated wildtype PDGFRA (IC50: 1-2 umol/L).",
                    "disease": {
                        "id": 216,
                        "name": "Cancer",
                        "display_name": "Cancer",
                        "doid": "162",
                        "url": "http://www.disease-ontology.org/?id=DOID:162"
                    },
                    "drugs": [
                        {
                            "id": 5,
                            "name": "Imatinib",
                            "ncit_id": "C62035",
                            "aliases": [
                                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 412,
                        "name": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.",
                        "citation": "Heinrich et al., 2003, J. Clin. Oncol.",
                        "citation_id": "14645423",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/14645423",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2003,
                            "month": 12,
                            "day": 1
                        },
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "status": "partially curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                },
                {
                    "id": 7514,
                    "name": "EID7514",
                    "description": "In an in vitro kinase study, the recombinant PDGFRA D842V mutant kinase demonstrated sensitivity to bosutinib treatment at concentrations of 1\u03bcM and 10\u03bcM (activity %: 25 and 6) when compared to wild type PDGFRA (activity %: 100 and 86).",
                    "disease": {
                        "id": 4,
                        "name": "Chronic Myeloid Leukemia",
                        "display_name": "Chronic Myeloid Leukemia",
                        "doid": "8552",
                        "url": "http://www.disease-ontology.org/?id=DOID:8552"
                    },
                    "drugs": [
                        {
                            "id": 520,
                            "name": "Bosutinib",
                            "ncit_id": "C60809",
                            "aliases": [
                                "SKI-606",
                                "SKI 606",
                                "Bosulif",
                                "4-Anilinobenzo(g)quinoline-3-carbonitrile",
                                "4-Anilino-3-quinolinecarbonitrile",
                                "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 1994,
                        "name": "Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.",
                        "citation": "Remsing Rix et al., 2009, Leukemia",
                        "citation_id": "19039322",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19039322",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2009,
                            "month": 3
                        },
                        "journal": "Leukemia",
                        "full_journal_title": "Leukemia",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 99,
                    "phenotypes": []
                }
            ],
            "variant_groups": [
                {
                    "id": 1,
                    "name": "Imatinib Resistance",
                    "description": "While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. ",
                    "variants": [
                        {
                            "id": 98,
                            "entrez_name": "PDGFRA",
                            "entrez_id": 5156,
                            "name": "D842I",
                            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
                            "gene_id": 38,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                }
                            ],
                            "civic_actionability_score": 4,
                            "coordinates": {
                                "chromosome": "4",
                                "start": 55152092,
                                "stop": 55152093,
                                "reference_bases": "GA",
                                "variant_bases": "AT",
                                "representative_transcript": "ENST00000257290.5",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 101,
                            "entrez_name": "PDGFRA",
                            "entrez_id": 5156,
                            "name": "I843DEL",
                            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
                            "gene_id": 38,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 107,
                                    "name": "inframe_deletion",
                                    "display_name": "Inframe Deletion",
                                    "so_id": "SO:0001822",
                                    "description": "An inframe non synonymous variant that deletes bases from the coding sequence.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001822"
                                }
                            ],
                            "civic_actionability_score": 5,
                            "coordinates": {
                                "chromosome": "4",
                                "start": 55152095,
                                "stop": 55152097,
                                "reference_bases": "ATC",
                                "variant_bases": null,
                                "representative_transcript": "ENST00000257290.5",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 2,
                            "entrez_name": "ABL1",
                            "entrez_id": 25,
                            "name": "BCR-ABL T315I",
                            "description": "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.",
                            "gene_id": 4,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                },
                                {
                                    "id": 120,
                                    "name": "transcript_fusion",
                                    "display_name": "Transcript Fusion",
                                    "so_id": "SO:0001886",
                                    "description": "A feature fusion where the deletion brings together transcript regions.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                                }
                            ],
                            "civic_actionability_score": 146,
                            "coordinates": {
                                "chromosome": "9",
                                "start": 133748283,
                                "stop": 133748283,
                                "reference_bases": "C",
                                "variant_bases": "T",
                                "representative_transcript": "ENST00000318560.5",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 241,
                            "entrez_name": "ABL1",
                            "entrez_id": 25,
                            "name": "BCR-ABL F317L",
                            "description": "BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.",
                            "gene_id": 4,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                },
                                {
                                    "id": 120,
                                    "name": "transcript_fusion",
                                    "display_name": "Transcript Fusion",
                                    "so_id": "SO:0001886",
                                    "description": "A feature fusion where the deletion brings together transcript regions.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                                }
                            ],
                            "civic_actionability_score": 114.5,
                            "coordinates": {
                                "chromosome": "9",
                                "start": 133748288,
                                "stop": 133748288,
                                "reference_bases": "T",
                                "variant_bases": "C",
                                "representative_transcript": "ENST00000318560.5",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 3,
                            "entrez_name": "ABL1",
                            "entrez_id": 25,
                            "name": "BCR-ABL E255K",
                            "description": "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.",
                            "gene_id": 4,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                },
                                {
                                    "id": 120,
                                    "name": "transcript_fusion",
                                    "display_name": "Transcript Fusion",
                                    "so_id": "SO:0001886",
                                    "description": "A feature fusion where the deletion brings together transcript regions.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                                }
                            ],
                            "civic_actionability_score": 73,
                            "coordinates": {
                                "chromosome": "9",
                                "start": 133738363,
                                "stop": 133738363,
                                "reference_bases": "G",
                                "variant_bases": "A",
                                "representative_transcript": "ENST00000318560.5",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 99,
                            "entrez_name": "PDGFRA",
                            "entrez_id": 5156,
                            "name": "D842V",
                            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
                            "gene_id": 38,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                }
                            ],
                            "civic_actionability_score": 100.5,
                            "coordinates": {
                                "chromosome": "4",
                                "start": 55152093,
                                "stop": 55152093,
                                "reference_bases": "A",
                                "variant_bases": "T",
                                "representative_transcript": "ENST00000257290.5",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 100,
                            "entrez_name": "PDGFRA",
                            "entrez_id": 5156,
                            "name": "D842Y",
                            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
                            "gene_id": 38,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                }
                            ],
                            "civic_actionability_score": 4,
                            "coordinates": {
                                "chromosome": "4",
                                "start": 55152092,
                                "stop": 55152092,
                                "reference_bases": "G",
                                "variant_bases": "T",
                                "representative_transcript": "ENST00000257290.5",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 102,
                            "entrez_name": "PDGFRA",
                            "entrez_id": 5156,
                            "name": "D842_I843delinsVM",
                            "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",
                            "gene_id": 38,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                }
                            ],
                            "civic_actionability_score": 4,
                            "coordinates": {
                                "chromosome": "4",
                                "start": 55152093,
                                "stop": 55152097,
                                "reference_bases": "ACATC",
                                "variant_bases": "TCATG",
                                "representative_transcript": "ENST00000257290.5",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        }
                    ],
                    "type": "variant_group"
                }
            ],
            "assertions": [],
            "variant_aliases": [
                "ASP842VAL",
                "RS121908585"
            ],
            "hgvs_expressions": [
                "NM_006206.4:c.2525A>T",
                "NP_006197.1:p.Asp842Val",
                "ENST00000257290.5:c.2525A>T",
                "NC_000004.11:g.55152093A>T"
            ],
            "clinvar_entries": [
                "13543"
            ],
            "allele_registry_id": "CA123194"
        },
        {
            "id": 113,
            "entrez_name": "RET",
            "entrez_id": 5979,
            "name": "M918T",
            "description": "RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.",
            "gene_id": 42,
            "type": "variant",
            "variant_types": [
                {
                    "id": 47,
                    "name": "missense_variant",
                    "display_name": "Missense Variant",
                    "so_id": "SO:0001583",
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                }
            ],
            "civic_actionability_score": 86,
            "coordinates": {
                "chromosome": "10",
                "start": 43617416,
                "stop": 43617416,
                "reference_bases": "T",
                "variant_bases": "C",
                "representative_transcript": "ENST00000355710.3",
                "chromosome2": null,
                "start2": null,
                "stop2": null,
                "representative_transcript2": null,
                "ensembl_version": 75,
                "reference_build": "GRCh37"
            },
            "evidence_items": [
                {
                    "id": 77,
                    "name": "EID77",
                    "description": "The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.",
                    "disease": {
                        "id": 15,
                        "name": "Thyroid Gland Medullary Carcinoma",
                        "display_name": "Thyroid Gland Medullary Carcinoma",
                        "doid": "3973",
                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
                    },
                    "drugs": [
                        {
                            "id": 24,
                            "name": "JAK2 Inhibitor AZD1480",
                            "ncit_id": "C91394",
                            "aliases": [
                                "AZD1480"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 91,
                        "name": "AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.",
                        "citation": "Couto et al., 2012, PLoS ONE",
                        "citation_id": "23056499",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23056499",
                        "open_access": true,
                        "pmc_id": "PMC3462763",
                        "publication_date": {
                            "year": 2012
                        },
                        "journal": "PLoS ONE",
                        "full_journal_title": "PloS one",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 113,
                    "phenotypes": []
                },
                {
                    "id": 78,
                    "name": "EID78",
                    "description": "Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer.",
                    "disease": {
                        "id": 15,
                        "name": "Thyroid Gland Medullary Carcinoma",
                        "display_name": "Thyroid Gland Medullary Carcinoma",
                        "doid": "3973",
                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
                    },
                    "drugs": [],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "Prognostic",
                    "clinical_significance": "Poor Outcome",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 92,
                        "name": "Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.",
                        "citation": "Egawa et al., 1998, Jpn. J. Clin. Oncol.",
                        "citation_id": "9839497",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/9839497",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 1998,
                            "month": 10
                        },
                        "journal": "Jpn. J. Clin. Oncol.",
                        "full_journal_title": "Japanese journal of clinical oncology",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 113,
                    "phenotypes": []
                },
                {
                    "id": 76,
                    "name": "EID76",
                    "description": "Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.",
                    "disease": {
                        "id": 15,
                        "name": "Thyroid Gland Medullary Carcinoma",
                        "display_name": "Thyroid Gland Medullary Carcinoma",
                        "doid": "3973",
                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
                    },
                    "drugs": [
                        {
                            "id": 23,
                            "name": "Motesanib",
                            "ncit_id": "C71896",
                            "aliases": []
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 90,
                        "name": "Anti-tumor activity of motesanib in a medullary thyroid cancer model.",
                        "citation": "Coxon et al., 2012, J. Endocrinol. Invest.",
                        "citation_id": "21422803",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21422803",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2012,
                            "month": 2
                        },
                        "journal": "J. Endocrinol. Invest.",
                        "full_journal_title": "Journal of endocrinological investigation",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 113,
                    "phenotypes": []
                },
                {
                    "id": 3696,
                    "name": "EID3696",
                    "description": "In an in vitro study, a MZ-CRC-1 cell line expressing RET M918T mutation (endogenous) demonstrated resistance to axitinib treatment (IC50> 5uM). Resistance was determined by assessing cell viability.",
                    "disease": {
                        "id": 15,
                        "name": "Thyroid Gland Medullary Carcinoma",
                        "display_name": "Thyroid Gland Medullary Carcinoma",
                        "doid": "3973",
                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
                    },
                    "drugs": [
                        {
                            "id": 519,
                            "name": "Axitinib",
                            "ncit_id": "C38718",
                            "aliases": [
                                "N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide",
                                "Inlyta",
                                "AG013736",
                                "AG-013736"
                            ]
                        }
                    ],
                    "rating": null,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Resistance",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 1921,
                        "name": "The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.",
                        "citation": "Verbeek et al., 2011, J. Clin. Endocrinol. Metab.",
                        "citation_id": "21470995",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21470995",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2011,
                            "month": 6
                        },
                        "journal": "J. Clin. Endocrinol. Metab.",
                        "full_journal_title": "The Journal of clinical endocrinology and metabolism",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 113,
                    "phenotypes": []
                },
                {
                    "id": 1365,
                    "name": "EID1365",
                    "description": "In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations. In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease. Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed.",
                    "disease": {
                        "id": 15,
                        "name": "Thyroid Gland Medullary Carcinoma",
                        "display_name": "Thyroid Gland Medullary Carcinoma",
                        "doid": "3973",
                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
                    },
                    "drugs": [
                        {
                            "id": 6,
                            "name": "Sorafenib",
                            "ncit_id": "C61948",
                            "aliases": [
                                "Bay-439006",
                                "BAY 43-9006",
                                "BA4 43 9006"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 928,
                        "name": "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.",
                        "citation": "Lam et al., 2010, J. Clin. Oncol.",
                        "citation_id": "20368568",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20368568",
                        "open_access": true,
                        "pmc_id": "PMC2881718",
                        "publication_date": {
                            "year": 2010,
                            "month": 5,
                            "day": 10
                        },
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 113,
                    "phenotypes": []
                },
                {
                    "id": 6950,
                    "name": "EID6950",
                    "description": "A patient with RET M918T-mutant medullary thyroid cancer metastatic to the liver and an acquired RET V804M gatekeeper resistance mutation, previously treated with six MKI regimens, experienced rapid reductions in tumor calcitonin, CEA and cell-free DNA, resolution of painful hepatomegaly and tumor-related diarrhea and a confirmed tumor Response under Treatment with RET-Inhibitor LOXO-292. Further preclinical experiments showed activity against cell lines with RET M918 mutation (and V804 Gatekeeper Mutation)",
                    "disease": {
                        "id": 15,
                        "name": "Thyroid Gland Medullary Carcinoma",
                        "display_name": "Thyroid Gland Medullary Carcinoma",
                        "doid": "3973",
                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
                    },
                    "drugs": [
                        {
                            "id": 601,
                            "name": "Selpercatinib",
                            "ncit_id": "C134987",
                            "aliases": [
                                "WHO 10967",
                                "Retevmo",
                                "6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril",
                                "RET Inhibitor LOXO-292",
                                "RET Kinase Inhibitor LOXO-292",
                                "LOXO-292"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "C",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 2677,
                        "name": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                        "citation": "Subbiah et al., 2018, Ann. Oncol.",
                        "citation_id": "29912274",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274",
                        "open_access": true,
                        "pmc_id": "PMC6096733",
                        "publication_date": {
                            "year": 2018,
                            "day": 1
                        },
                        "journal": "Ann. Oncol.",
                        "full_journal_title": "Annals of oncology : official journal of the European Society for Medical Oncology",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 113,
                    "phenotypes": []
                },
                {
                    "id": 74,
                    "name": "EID74",
                    "description": "In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.",
                    "disease": {
                        "id": 15,
                        "name": "Thyroid Gland Medullary Carcinoma",
                        "display_name": "Thyroid Gland Medullary Carcinoma",
                        "doid": "3973",
                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
                    },
                    "drugs": [],
                    "rating": 5,
                    "evidence_level": "B",
                    "evidence_type": "Diagnostic",
                    "clinical_significance": "Positive",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 44,
                        "name": "Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.",
                        "citation": "Elisei et al., 2008, J. Clin. Endocrinol. Metab.",
                        "citation_id": "18073307",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18073307",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2008,
                            "month": 3
                        },
                        "journal": "J. Clin. Endocrinol. Metab.",
                        "full_journal_title": "The Journal of clinical endocrinology and metabolism",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 113,
                    "phenotypes": []
                },
                {
                    "id": 7710,
                    "name": "EID7710",
                    "description": "In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and 13.9% were RET mutation-negative. Sixteen patients were RAS mutation-positive. Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.14-0.38; P\u2009<\u2009.0001). \nPatients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53).\nThe RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR 0.15).",
                    "disease": {
                        "id": 15,
                        "name": "Thyroid Gland Medullary Carcinoma",
                        "display_name": "Thyroid Gland Medullary Carcinoma",
                        "doid": "3973",
                        "url": "http://www.disease-ontology.org/?id=DOID:3973"
                    },
                    "drugs": [
                        {
                            "id": 144,
                            "name": "Cabozantinib",
                            "ncit_id": "C52200",
                            "aliases": [
                                "N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide",
                                "1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 3061,
                        "name": "Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.",
                        "citation": "Sherman et al., 2016, Cancer",
                        "citation_id": "27525386",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27525386",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2016,
                            "month": 12,
                            "day": 15
                        },
                        "journal": "Cancer",
                        "full_journal_title": "Cancer",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 113,
                    "phenotypes": []
                }
            ],
            "variant_groups": [
                {
                    "id": 6,
                    "name": "Motesanib Resistance",
                    "description": "RET activation is a common oncogenic marker of medullary thyroid carcinoma. Treatment of these patients with the targeted therapeutic motesanib has shown to be effective. However, the missense mutations C634W and M918T have shown to confer motesanib resistance in cell lines. ",
                    "variants": [
                        {
                            "id": 112,
                            "entrez_name": "RET",
                            "entrez_id": 5979,
                            "name": "C634W",
                            "description": "RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.",
                            "gene_id": 42,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                }
                            ],
                            "civic_actionability_score": 3,
                            "coordinates": {
                                "chromosome": "10",
                                "start": 43609950,
                                "stop": 43609950,
                                "reference_bases": "C",
                                "variant_bases": "G",
                                "representative_transcript": "ENST00000355710.3",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 113,
                            "entrez_name": "RET",
                            "entrez_id": 5979,
                            "name": "M918T",
                            "description": "RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.",
                            "gene_id": 42,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                }
                            ],
                            "civic_actionability_score": 86,
                            "coordinates": {
                                "chromosome": "10",
                                "start": 43617416,
                                "stop": 43617416,
                                "reference_bases": "T",
                                "variant_bases": "C",
                                "representative_transcript": "ENST00000355710.3",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        }
                    ],
                    "type": "variant_group"
                }
            ],
            "assertions": [],
            "variant_aliases": [
                "RS74799832",
                "MET918THR"
            ],
            "hgvs_expressions": [
                "NM_020975.4:c.2753T>C",
                "NP_065681.1:p.Met918Thr",
                "ENST00000355710.3:c.2753T>C",
                "NC_000010.10:g.43617416T>C"
            ],
            "clinvar_entries": [
                "13919"
            ],
            "allele_registry_id": "CA009082"
        },
        {
            "id": 1686,
            "entrez_name": "ACVR1",
            "entrez_id": 90,
            "name": "G328V",
            "description": "",
            "gene_id": 154,
            "type": "variant",
            "variant_types": [
                {
                    "id": 47,
                    "name": "missense_variant",
                    "display_name": "Missense Variant",
                    "so_id": "SO:0001583",
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                }
            ],
            "civic_actionability_score": 30,
            "coordinates": {
                "chromosome": "2",
                "start": 158622516,
                "stop": 158622516,
                "reference_bases": "C",
                "variant_bases": "A",
                "representative_transcript": "ENST00000434821.1",
                "chromosome2": null,
                "start2": null,
                "stop2": null,
                "representative_transcript2": null,
                "ensembl_version": 75,
                "reference_build": "GRCh37"
            },
            "evidence_items": [
                {
                    "id": 8035,
                    "name": "EID8035",
                    "description": "Using mouse models, the authors demonstrated that Acvr1G328V arrested the differentiation of oligodendroglial lineage cells to generate high-grade diffuse gliomas. Using a cellular NanoBRET target engagement assay, they identified the binding between E6201 and ACVR1 with half maximal inhibitory concen- tration [IC50] \u2248 0.25 mM). Furthermore, in primary brainstem glial cells, they demonstrated that E6201 had a larger suppressive effect on BMP signaling pathway activation induced by mutant ACVR1 than by wild-type ACVR1. In addition, to obtain mechanistic insights into the inhibitory effect of E6201 on ACVR1, they solved the 1.5-A \u030a structure of ACVR1 in complex with its interacting partner E6201 by X-ray crystallography. And they showed that E6201 occupied the ATP-binding pocket of ACVR1 with a binding position similar to that in the equivalent MEK1 complex.",
                    "disease": {
                        "id": 2950,
                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "doid": "0080684",
                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
                    },
                    "drugs": [
                        {
                            "id": 15211,
                            "name": "MEK-1/MEKK-1 Inhibitor E6201",
                            "ncit_id": "C79848",
                            "aliases": [
                                "E6201"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 3226,
                        "name": "Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.",
                        "citation": "Fortin et al., 2020, Cancer Cell",
                        "citation_id": "32142668",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/32142668",
                        "open_access": null,
                        "pmc_id": null,
                        "publication_date": {
                            "year": 2020,
                            "month": 2,
                            "day": 21
                        },
                        "journal": "Cancer Cell",
                        "full_journal_title": "Cancer cell",
                        "status": "submitted",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 1686,
                    "phenotypes": []
                },
                {
                    "id": 4846,
                    "name": "EID4846",
                    "description": "Sequencing of 39 pediatric midline high-grade astrocytomas identified 5 patients with ACVR1 mutations. The authors identified an increase in endogenous phospho-SMAD1/5/8 signal in diffuse intrinsic pontine glioma (DIPG) cells harboring ACVR1 G328V, with corresponding increase in phospho-SMAD1/5/8 staining as well. By PCR, the authors show strong increase in fold change of mRNA expression in downstream proteins of the ACVR1/BMP pathway, ID, ID2, ID3 and SNAI1 in ACVR1-mutant DIPG cell line compared to glioblastoma cells (KNS42 cells). These activating ACVR1 mutations were exclusively in midline high grade astrocytomas (P = 0.0040, Fisher's exact test).",
                    "disease": {
                        "id": 2950,
                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "doid": "0080684",
                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
                    },
                    "drugs": [],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "Diagnostic",
                    "clinical_significance": "Positive",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2149,
                        "name": "Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.",
                        "citation": "Fontebasso et al., 2014, Nat. Genet.",
                        "citation_id": "24705250",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705250",
                        "open_access": true,
                        "pmc_id": "PMC4282994",
                        "publication_date": {
                            "year": 2014,
                            "month": 5
                        },
                        "journal": "Nat. Genet.",
                        "full_journal_title": "Nature genetics",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 1686,
                    "phenotypes": []
                },
                {
                    "id": 6955,
                    "name": "EID6955",
                    "description": "In a study sequencing 61 patients (median age 6.3) with diffuse intrinsic pontine glioma (DIPG), 12 variants affecting ACVR1 were observed. Five patients had G328V within the kinase domain. The ACVR1 G328V mutation was expressed using the pCDH511b vector in immortalized normal human astrocytes (iNHAs) where it activated downstream BMP signaling and enhanced cell growth. Activating ACVR1 mutations are recurrent and support diagnosis of high grade glioma. PEDIATRIC",
                    "disease": {
                        "id": 2950,
                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "doid": "0080684",
                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
                    },
                    "drugs": [],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "Diagnostic",
                    "clinical_significance": "Positive",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2680,
                        "name": "Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.",
                        "citation": "Buczkowicz et al., 2014, Nat. Genet.",
                        "citation_id": "24705254",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705254",
                        "open_access": true,
                        "pmc_id": "PMC3997489",
                        "publication_date": {
                            "year": 2014,
                            "month": 5
                        },
                        "journal": "Nat. Genet.",
                        "full_journal_title": "Nature genetics",
                        "status": "partially curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 1686,
                    "phenotypes": []
                },
                {
                    "id": 6092,
                    "name": "EID6092",
                    "description": "To investigate the specific role of ACVR1 mutations in the context of DIPG, a panel of four DIPG patient-derived primary cultures (and one thalamic paediatric GBM culture harbouring an H3F3A K27M mutation), representing two ACVR1 mutations (R206H and G328V) and three wild-type lines were assembled. RNAseq or Sanger data confirmed expression of mutant alleles. Treatment with the selective ALK2 inhibitor LDN-19318917 resulted in marked inhibition of cell viability in all cells, with GI50 values ranging from 0.86 \u2013 2.1 \u03bcM, approximately 10-fold lower than the less potent parent compound dorsomorphin, with a trend towards increased sensitivity in the mutant cultures (p=0.10, F-test)",
                    "disease": {
                        "id": 2950,
                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "doid": "0080684",
                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
                    },
                    "drugs": [
                        {
                            "id": 604,
                            "name": "ALK2 Inhibitor LDN-193189",
                            "ncit_id": null,
                            "aliases": []
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "Predictive",
                    "clinical_significance": "Sensitivity/Response",
                    "evidence_direction": "Supports",
                    "variant_origin": "Somatic",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 2448,
                        "name": "Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.",
                        "citation": "Taylor et al., 2014, Nat. Genet.",
                        "citation_id": "24705252",
                        "source_type": "PubMed",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24705252",
                        "open_access": true,
                        "pmc_id": "PMC4018681",
                        "publication_date": {
                            "year": 2014,
                            "month": 5
                        },
                        "journal": "Nat. Genet.",
                        "full_journal_title": "Nature genetics",
                        "status": "fully curated",
                        "is_review": false,
                        "clinical_trials": []
                    },
                    "variant_id": 1686,
                    "phenotypes": []
                }
            ],
            "variant_groups": [
                {
                    "id": 23,
                    "name": "ACVR1 kinase domain mutation",
                    "description": "",
                    "variants": [
                        {
                            "id": 1686,
                            "entrez_name": "ACVR1",
                            "entrez_id": 90,
                            "name": "G328V",
                            "description": "",
                            "gene_id": 154,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                }
                            ],
                            "civic_actionability_score": 30,
                            "coordinates": {
                                "chromosome": "2",
                                "start": 158622516,
                                "stop": 158622516,
                                "reference_bases": "C",
                                "variant_bases": "A",
                                "representative_transcript": "ENST00000434821.1",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 2280,
                            "entrez_name": "ACVR1",
                            "entrez_id": 90,
                            "name": "G328W",
                            "description": "",
                            "gene_id": 154,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                }
                            ],
                            "civic_actionability_score": 0,
                            "coordinates": {
                                "chromosome": "2",
                                "start": 158622517,
                                "stop": 158622517,
                                "reference_bases": "C",
                                "variant_bases": "A",
                                "representative_transcript": "ENST00000263640.3",
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": 75,
                                "reference_build": "GRCh37"
                            }
                        },
                        {
                            "id": 2283,
                            "entrez_name": "ACVR1",
                            "entrez_id": 90,
                            "name": "G328E",
                            "description": "This mutation occurs within the kinase domain of ACVR1 and has been shown to be activating of downstream BMP signaling with increased cell proliferation in cells overexpressing this variant.",
                            "gene_id": 154,
                            "type": "variant",
                            "variant_types": [
                                {
                                    "id": 47,
                                    "name": "missense_variant",
                                    "display_name": "Missense Variant",
                                    "so_id": "SO:0001583",
                                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                                },
                                {
                                    "id": 160,
                                    "name": "gain_of_function_variant",
                                    "display_name": "Gain Of Function Variant",
                                    "so_id": "SO:0002053",
                                    "description": "A sequence variant whereby new or enhanced function is conferred on the gene product.",
                                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0002053"
                                }
                            ],
                            "civic_actionability_score": 7.5,
                            "coordinates": {
                                "chromosome": null,
                                "start": null,
                                "stop": null,
                                "reference_bases": null,
                                "variant_bases": null,
                                "representative_transcript": null,
                                "chromosome2": null,
                                "start2": null,
                                "stop2": null,
                                "representative_transcript2": null,
                                "ensembl_version": null,
                                "reference_build": null
                            }
                        }
                    ],
                    "type": "variant_group"
                }
            ],
            "assertions": [
                {
                    "id": 9,
                    "type": "assertion",
                    "name": "AID9",
                    "summary": "Supports diagnosis of diffuse intrinsic pontine glioma.",
                    "description": "ACVR1 G328V mutations occur within the kinase domain, leading to activation of downstream signaling. Exclusively seen in high-grade pediatric gliomas, supporting diagnosis of diffuse intrinsic pontine glioma.",
                    "gene": {
                        "name": "ACVR1",
                        "id": 154
                    },
                    "variant": {
                        "name": "G328V",
                        "id": 1686
                    },
                    "disease": {
                        "id": 2950,
                        "name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "display_name": "Diffuse Midline Glioma, H3 K27M-mutant",
                        "doid": "0080684",
                        "url": "http://www.disease-ontology.org/?id=DOID:0080684"
                    },
                    "drugs": [],
                    "evidence_type": "Diagnostic",
                    "evidence_direction": "Supports",
                    "clinical_significance": "Positive",
                    "fda_regulatory_approval": false,
                    "status": "accepted"
                }
            ],
            "variant_aliases": [
                "GLY328VAL",
                "RS387906589"
            ],
            "hgvs_expressions": [
                "NM_001105.4:c.983G>T",
                "NP_001096.1:p.Gly328Val",
                "NC_000002.11:g.158622516C>A",
                "ENST00000434821.1:c.983G>T"
            ],
            "clinvar_entries": [
                "376363"
            ],
            "allele_registry_id": "CA16602802"
        }
    ]
}